Management of immune checkpoint inhibitor‐related dermatologic adverse events

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy‐related adverse events. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic toxicities including Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms are rare. In this review, we summarize guidelines of management of immunotherapy‐related toxicities, case reports, and proposed treatment recommendation.